Title |
An Expanding Role for Interleukin-1 Blockade from Gout to Cancer
|
---|---|
Published in |
Molecular Medicine, December 2014
|
DOI | 10.2119/molmed.2014.00232 |
Pubmed ID | |
Authors |
Charles Anthony Dinarello |
Abstract |
There is an expanding role for interleukin (IL)-1 in diseases from gout to cancer. More than any other cytokine family, the IL-1 family is closely linked to innate inflammatory and immune responses. This linkage is because the cytoplasmic segment of all members of the IL-1 family of receptors contains a domain, which is highly homologous to the cytoplasmic domains of all toll-like receptors (TLRs). This domain, termed "toll IL-1 receptor (TIR) domain," signals as does the IL-1 receptors; therefore, inflammation due to the TLR and the IL-1 families is nearly the same. Fundamental responses such as the induction of cyclo-oxygenase type 2, increased surface expression of cellular adhesion molecules and increased gene expression of a broad number of inflammatory molecules characterizes IL-1 signal transduction as it does for TLR agonists. IL-1β is the most studied member of the IL-1 family because of its role in mediating autoinflammatory disease. However, a role for IL-1α in disease is being validated because of the availability of a neutralizing monoclonal antibody to human IL-1α. There are presently three approved therapies for blocking IL-1 activity. Anakinra is a recombinant form of the naturally occurring IL-1 receptor antagonist, which binds to the IL-1 receptor and prevents the binding of IL-1β as well as IL-1α. Rilonacept is a soluble decoy receptor that neutralizes primarily IL-1β but also IL-1α. Canakinumab is a human monoclonal antibody that neutralizes only IL-1β. Thus, a causal or significant contributing role can be established for IL-1β and IL-1α in human disease. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Russia | 1 | <1% |
Brazil | 1 | <1% |
Unknown | 116 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 15 | 13% |
Researcher | 13 | 11% |
Student > Ph. D. Student | 12 | 10% |
Student > Postgraduate | 11 | 9% |
Student > Doctoral Student | 9 | 8% |
Other | 28 | 24% |
Unknown | 30 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 40 | 34% |
Biochemistry, Genetics and Molecular Biology | 14 | 12% |
Agricultural and Biological Sciences | 11 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
Immunology and Microbiology | 5 | 4% |
Other | 11 | 9% |
Unknown | 32 | 27% |